Jefferies Group LLC Chemo Centryx, Inc. Call Options Transaction History

Jefferies Group LLC

$10.2 Billion
Q3 2022

Call Options

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held	SEC Form
Q4 2021 Feb 14, 2022	SELL	$18.38 - $40.5 $580,808 - $1.28 Million	-31,600 Closed	0 $0
Q3 2021 Sep 21, 2023	BUY	$13.18 - $19.83 $379,584 - $571,104	28,800 Added 1028.57%	31,600 $540,000
Q3 2021 Nov 15, 2021	BUY	$13.18 - $19.83 $379,584 - $571,104	28,800 Added 1028.57%	31,600 $540,000
Q2 2021 Sep 21, 2023	BUY	$9.59 - $50.88 $26,852 - $142,464	2,800 New	2,800 $37,000
Q2 2021 Aug 20, 2021	SELL	$9.59 - $50.88 $2.66 Million - $14.1 Million	-277,200 Reduced 99.0%	2,800 $37,000
Q2 2021 Aug 16, 2021	BUY	$9.59 - $50.88 $2.65 Million - $14.1 Million	276,200 Added 7268.42%	280,000 $37,000
Q4 2019 Feb 13, 2020	BUY	$6.81 - $39.55 $25,878 - $150,290	3,800 New	3,800 $150,000

Others Institutions Holding CCXI

# of Institutions

6

Shares Held

66.3K

Call Options Held

0

Put Options Held

0

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jefferies Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jefferies Group LLC with notifications on news.